| 翻訳と辞書 |
Epratuzumab
Epratuzumab (planned trade name LymphoCide) is a humanized monoclonal antibody. Potential uses may be found in oncology and in treatment of inflammatory autoimmune disorders, such as systemic lupus erythematosus (SLE).〔(Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties ) Clinical Cancer Research Vol. 9, September 1, 2003 ''free full text''〕〔(Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab ) Clinical Cancer Research Vol. 11, July 15, 2005 ''free full text''〕
==Clinical trials==
A clinical trial for relapsed adult acute lymphoblastic leukemia (ALL) has reported initial results.〔
Results have been published for a phase II trial in untreated follicular lymphoma.〔
Early results from a phase II trial for Diffuse large B-cell lymphoma (DLBCL) were encouraging.〔
The manufacturers in August 2009 announced success in early trials against SLE,〔Reuters: (UCB and Immunomedics Announce Positive Results for Epratuzumab Phase IIb Study in Systemic Lupus Erythematosus (SLE) )〕 and started two Phase III clinical trials.
July 2015 : Both phase III trials (EMBODY1/2) for SLE failed to meet their primary endpoint.〔(Epratuzumab flunks two Phase 3 studies; Immunomedics plummets 42% premarket. July 28 2015 )〕
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Epratuzumab」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|